Journal of Vascular Surgery Angiotensin Receptor Blockers in Abdominal Aortic Aneurysm Management: Evidence Supporting the TEDY Trial Ronald L. Dalman, MD, Haojun Xuan, MD, Wei Wang, MD, PhD, Hiroki Tanaka, MD, PhD, Naoki Fujimura, MD, PhD, Baohui Xu, MD, PhD Journal of Vascular Surgery Volume 64, Issue 2, (August 2016) DOI: 10.1016/j.jvs.2016.05.009 Copyright © 2016 Terms and Conditions
Fig AT1 inhibition suppresses the formation and progression of experimental abdominal aortic aneurysms (AAAs) in an exogenous angiotensin II-independent mouse model. A-D, AT1a deficiency attenuated porcine pancreatic elastase (PPE) infusion-induced aortic enlargement (A), medial elastin degradation (EVG stain; B), mural CD68+ macrophage accumulation (C), and CD31+ neoangiogenesis (D). KO, Knockout; WT, wild type; n = 5 mice per group. E-H, Intervention with either telmisartan treatment regimen suppressed aneurysm progression (E), medial elastin degradation (F), mural CD68+ macrophage density (G), and neoangiogenesis (H). n = 10-15 mice per group after PPE infusion. Telmisartan treatment beginning 7 days before and ending 13 days after PPE infusion downregulated the aortic mRNA levels of CCL5 and matrix metalloproteinases 2 and 9 (MMP2 and MMP9). n = 5 mice in each group. Statistical analysis: one-way analysis of variance (A, E) or nonparametric Mann-Whitney test (B-D, F-I), ∗P < .05 and ∗∗P < .01 compared with WT mice (A-D) or no telmisartan treatment group (none; E-I). Journal of Vascular Surgery 2016 64, DOI: (10.1016/j.jvs.2016.05.009) Copyright © 2016 Terms and Conditions